Objective-To evaluate the efficacy and safety of the second generation dihydropyridine calcium channel blocker lacidipine in patients with heart failure. Design-Placebo controlled, parallel group, double blind study over 8 weeks. Setting-General community hospital in Breda, The Netherlands. Patients-A random sample was studied of 25 outpatients with symptoms of mild to moderate heart failure, despite treatment with diuretics, digoxin, and angiotensin converting enzyme inhibitors. Their mean age was 65 years, with mean left ventricular ejection fraction of 0-24 and a peak oxygen consumption of 14*4 mllminlkg. Two patients dropped out on lacidipine, one patient on placebo. Intervention-Treatment with lacidipine 4 mg once daily or placebo for eight weeks. Main outcome measure-Cardiopulmonary exercise testing, invasive haemodynamics, and plasma neurohormones. Results-Treatment with lacidipine 4 mg once daily, as compared to placebo treatment, significantly improved peak oxygen consumption (P < 0.02), cardiac index (P < 0.01), and stroke volume (P < 0.03) paralleled by a decrease in systemic vascular resistance (P < 0.03) and arteriovenous oxygen content difference (P < 0.01).
14*4 mllminlkg. Two patients dropped out on lacidipine, one patient on placebo. Intervention-Treatment with lacidipine 4 mg once daily or placebo for eight weeks. Main outcome measure-Cardiopulmonary exercise testing, invasive haemodynamics, and plasma neurohormones. Results-Treatment with lacidipine 4 mg once daily, as compared to placebo treatment, significantly improved peak oxygen consumption (P < 0.02), cardiac index (P < 0.01), and stroke volume (P < 0.03) paralleled by a decrease in systemic vascular resistance (P < 0.03) and arteriovenous oxygen content difference (P < 0.01).
Plasma noradrenaline, plasma renin activity, and aldosterone values did not differ between lacidipine and placebo. Conclusions-This second generation dihydropyridine may be of value as an adjunct to standard treatment in congestive heart failure patients.
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Chronic heart failure is a major public health problem. Despite angiotensin converting enzyme inhibitors, digoxin, and diuretics, both mortality and morbidity remain high. ' There is a compelling need for therapeutic alternatives or additives. 2 The direct arterial vasodilator effect of the dihydropyridine calcium channel blockers results in a reduction of systemic vascular resistance. This may be beneficial as an adjunct to the indirect vasodilating angiotensin converting enzyme inhibitors. However, vasodilatation-induced neurohumoral activation and negative inotropic effects of the first generation of these dihydropyridines resulted in a disappointing outcome in heart failure studies.34 In recent years more selective dihydropyridine calcium antagonists have been developed, typified by a slow onset of action, a long plasma half life, and a narrow trough to peak ratio. This may result in less neurohormonal activation, while high vascular selectivity may lead to less negative inotropic effects. Lacidipine is one such new dihydropyridine derived vascular selective calcium antagonist with a slow onset and longer duration of action,5 which has been proven effective as an antihypertensive agent.67
This study, which is the first using lacidipine in heart failure patients, was designed to explore the efficacy and safety of lacidipine when given in conjunction with angiotensin converting enzyme inhibitors, digoxin, and diuretics. 
Results

PATIENTS
Twenty five patients entered the study. Baseline characteristics are presented in table 1. There were no significant differences between the groups at baseline. Before unblinding of the trial code three patients were excluded from the efficacy analysis as they had not all had their final assessments performed according to the protocol; one patient (placebo) had a cerebrovascular accident caused by a cerebral tumour; one lacidipine patient had a lung metastasis of a Grawitz tumour (unknown at the time of inclusion); one patient (lacidipine) experienced worsening heart failure necessitating hospital admission. The remaining 22 patients form the study population for the efficacy indices: 12 were randomised to placebo and 10 to lacidipine. For peak oxygen consumption two additional analyses were performed with inclusion of the lacidipine patient who had been admitted to hospital with worsening heart failure. In the first analysis for peak oxygen consumption at the final visit this patient's baseline peak oxygen value was used (that is, no change); in the second analysis the worst recorded value for peak oxygen consumption was taken.
CARDIOPULMONARY EXERCISE TEST
Peak oxygen consumption increased by 1-3 ml/min/kg to 16a1 (SD 3 4) with lacidipine and decreased by 0-6 ml/min/kg to 13-6 (2 2) with placebo (P<0-02 between treatments, fig 2) . The two additional analyses revealed similar results with P values of 0-02 and 0-06 respectively. Exercise duration increased by 28 s to 538 (215) s with lacidipine, and decreased by 4 s to 486 (145) s with placebo (P = NS). At rest, submaximal and peak exercise, heart rate, and blood pressure remained unchanged (table 2) . found an improvement in haemodynamic variables and neurohormones after felodipine.
Amlodipinel" decreased neurohormonal activation and prolonged exercise duration. 8
Nisoldipine improved clinical status and did not influence neurohormones; however, the initial effects on haemodynamic variables disappeared after three months.'4 Dunselman et all5 found an improvement in haemodynamics and in exercise duration after eight weeks of treatment with felodipine. Tan et al16 reported an improvement in haemodynamic variables with felodipine, but no improvement in clinical condition or exercise capacity after three weeks. Nicardipine resulted in worsening of heart failure and neurohumoral activation P < 0.03 after four months of treatment."3 Apart from lack of uniformity in design and methodology of these studies, it is important to realise that no two dihydropyridines are the same, and that the differences in vasoselectivity, plasma half life, and peak to trough plasma level ratio may partly explain the observed differences in study results. 8
A cautious approach to our results with r eight lacidipine on neurohumoral activation is justified as this was a small study. However, there are several possible explanations for the lack of overt neurohumoral activation despite pronounced arterial vasodilatation observed in ry analy-our study and others. First, it may be caused )t signifi-by the increase in cardiac output which may be sufficient to compensate for the decrease in blood pressure, thereby abolishing the need for a heightened compensatory neurohumoral mechanism. If this explanation is true one the new should have expected the same results with blocker other vasodilators like hydralazine which also e, shows result in a significant increase in cardiac outh 4 mg put, though associated with neurohumoral n with activation. Second, the confounding effects of thibitors, comedication have to be considered as a possk oxygen ible source of the observed beneficial effects of cardiac lacidipine in our study. Effects of both iccompa-angiotensin converting enzyme inhibitors and lar resis-digoxin in heart failure patients may be partly 1 blood related to their effect on neurohumoral mechrt failure anisms, decreasing the activation of the neurohu-sympathetic nervous system and the renintion but angiotensin axis,'8-20 thereby neutralising or placebo. obscuring a possible neurohumoral activation hypoten-of dihydropyridines. Third, resetting of although baroreceptor sensitivity by dihydropyridines, hospital resulting in less sympathetic activation, may play a role. '7 Finally, the pharmacokinetic proof 14-4 file of this new dihydropyridine, typified by a ic capac-slow onset of action, longer duration of action, gen con-and narrow trough to peak variability, may lent with attribute to this effect. n cardiac
Although haemodynamic and exercise vari- group.bmj.com on October 15, 2017 -Published by http://heart.bmj.com/ Downloaded from ables improved significantly, no changes in left ventricular systolic function at rest were found. Ejection fraction is a strong prognostic marker in heart failure patients21 but our findings may underline the fact that for evaluation of drug induced haemodynamic changes in a small patient group, this non-invasive assessment lacks sensitivity.22 However, the lack of change in left and right ejection fractions and shortening fraction suggests that lacidipine treatment did not result in a deterioration of systolic function, as described with the first generation of dihydropyridines.2425
STUDY LIMITATIONS
The number of patients studied was small and therefore the data must be interpreted with caution. An imbalance in sex over the two treatment groups existed (albeit non-significant) which may have influenced the outcome. We cannot rule out the possibility that a neurohumoral counterregulation could go undetected owing to the small number of patients in our study and the large variation in neurohumoral plasma levels.
CLINICAL IMPLICATIONS The aetiology of heart failure is coronary artery disease or hypertension in 60-70% of cases,26 27 and these patients may benefit from the use of additional calcium channel blockers since they lead to both peripheral and coronary vasodilatation. 28 Both the prevention and the treatment trial of the studies of left ventricular dysfunction (SOLVD) showed that more than 30% of patients fulfilling the entry criteria were using a calcium channel blocker,' 29 indicating that physicians keep patients on these drugs prescribed for hypertension or coronary artery disease even when symptomatic systolic dysfunction develops. This study in patients with heart failure showed that lacidipine, in conjunction with angiotensin converting enzyme inhibitors, digoxin, and diuretics, improves aerobic capacity, maintains vasodilatation, does not have a major influence on neurohumoral activity, and is generally well tolerated. When a physician considers prescribing a calcium channel blocker to a patient with heart failure-because of hypertension or angina pectoris-second generation calcium antagonists like lacidipine may be preferred to the first generation calcium antagonists. However, with respect to the long term efficacy and safety of second generation dihydropyridines in heart failure, the results of the V-Heft III [evaluating felodipine compared to placebo in addition to diuretics, angiotensin converting enzyme inhibitors, and digoxin], and the Praise study [amlodipine versus placebo in addition to angiotensin converting enzyme inhibitors]'4 must be awaited.
